EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.

doi:10.1038/s41388-020-1208-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.

Oncogene - 1 Apr 2020

Struve Nina, Binder Zev A, Stead Lucy F, Brend Tim, Bagley Stephen J, Faulkner Claire, Ott Leonie, Müller-Goebel Justus, Weik Anna-Sophie, Hoffer Konstantin, Krug Leonie, Rieckmann Thorsten, Bußmann Lara, Henze Marvin, Morrissette Jennifer J D, Kurian Kathreena M, Schüller Ulrich, Petersen Cordula, Rothkamm Kai, O Rourke Donald M, Short Susan C, Kriegs Malte

Abstract excerpt

The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but its impact on therapy response is still under controversial debate. Here we wanted to test if EGFRvIII influences the sensitivity towards the alkylating agent temozolomide (TMZ). Therefore, we retrospectively analyzed the survival of 336 GBM patients, demonstrating that under standard treatment,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemoradiotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to MutS Homolog 2 Protein

Share to Temozolomide

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32066879
DOI: 10.1038/s41388-020-1208-5
PMCID: PMC7142016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.PMID 32066879Read ↗

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistanceSemantic proximity Read ↗

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read ↗

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.Semantic proximity Read ↗

Variations in DNA Repair Genes and Intratumoral Genetic Heterogeneity in Temozolomide-Resistant Glioblastoma.Semantic proximity Read ↗

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Semantic proximity Read ↗

The DNA methylome of glioblastoma multiforme.Semantic proximity Read ↗

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genesSemantic proximity Read ↗

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cellsSemantic proximity Read ↗

Expression of EGFRvIII in Glioblastoma: Prognostic Significance RevisitedSemantic proximity Read ↗

The Importance of Mutational Drivers in GBM.Semantic proximity Read ↗

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysisSemantic proximity Read ↗

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.